The Headlines
Dechra is a company with a track record of growth. Our pharmaceutical sales revenue topped £189 m in 2013, with 89% of this coming from Europe. We continue to invest in new products with 8 novel products and 3 differentiated generics in our product pipeline.
Despite the fact that we have grown rapidly, we have stayed true to who we are. We have not forgotten our roots and we remain a small and responsive company at heart.
What we do best
Our key areas of expertise span endocrinology, dermatology, cardiology, water soluble powder products and injectable antibiotics, anaesthetics and analgesics, equine medicine and diet and nutrition. Our major products include:
- Vetoryl® Capsules, for the treatment of canine hyperadrenocorticism (Cushing's syndrome)
- Dermatology brands Canaural®, Fuciderm® Gel and Malaseb® Shampoo
- Felimazole® Tablets, for treating feline hyperthyroidism
- Added value pharmaceuticals - Cardisure® and Forthyron®, for treating canine congestive heart disease and hypothyroidism respectively
- Cyclospray® an antibiotic spray for treating claw / hoof problems like Mortallaro’s disease in cattle and superficial wounds
- Soludox 50% and Octacillin® for treating respiratory and enteric disease in pigs and poultry
- Equipalazone®, the anti-inflammatory and analgesic for equine musculoskeletal disorders
- SPECIFIC™, a complete, vet exclusive premium diet range that provides precise nutritional solutions throughout the lives of cats and dogs.
Navigation